Skip to main content

Advertisement

Table 1 Tumor, patient, and treatment-related characteristics. NT+S neoadjuvant treatment plus surgery, NT−S neoadjuvant treatment without surgery, IQR interquartile range, AC adenocarcinoma, SCC squamous cell carcinoma, nCRT neoadjuvant chemoradiotherapy, nCT neoadjuvant chemotherapy

From: Analysis of patients scheduled for neoadjuvant therapy followed by surgery for esophageal cancer, who never made it to esophagectomy

  NT+S NT−S All p
No. of patients 565 83.2% 114 16.8% 679  
Gender
 Male 433 76.6% 89 78.1% 522 0.808
 Female 132 23.4% 25 21.9% 157
Age
 Mean (range) 61 (27–83) 65 (32–86) 62 (27–86) 0.002
Time frame
 Before 2011 274 48.5% 62 54.4% 336 0.148
 From 2011 291 51.5% 52 45.6% 343
Histology
 AC 378 66.9% 52 45.6% 430 < 0.0001
 SCC 187 33.1% 62 54.4% 249
Clinical stage
 cT1 2 0.4%   0.0% 2 0.400
 cT2 55 9.8% 7 6.1% 62
 cT3 433 77.1% 87 76.3% 520
 cT3–4 38 6.8% 14 12.3% 50
 cT4 33 5.9% 6 5.3% 45
Clinical N
 cN negative 53 9.4% 11 9.6% 64 0.862
 cN positive 512 90.6% 103 90.4% 615
Type of treatment
 nCRT 491 86.9% 93 81.6% 584 0.140
 nCT 74 13.1% 21 18.4% 95